Start Free Trial
Pricing
Log In
Log In
Upgrade browser for full Crunchbase experience. You're accessing Crunchbase in a browser that is no longer supported.
Learn More
VIVUS Logo
VIVUS Growth Score
91
CB Rank
110197
Heat Score
66
VIVUS is a drug-development company dedicated to the development and commercialization of next-generation therapeutic products
Founded
obfuscation
PublicPost-IPO Equity Mountain View, California, United States51-100 www.vivus.com
Biopharma
Biotechnology
Health Care
Overview

VIVUS
Total Funding
obfuscation
Growth Score
91
Heat Score
66

Total Funding
obfuscation
obfuscation
Post-IPO Equity raised
obfuscation
Growth Score91
11 pts
in past quarter
Heat Score 66
1 pts
in past quarter

Company Performance Metrics

Score
Trend
AI Content may contain mistakes and is not legal, financial or investment advice.Learn more.
Growth Score - The measure of growth based on company activity, operational metrics, and investments
Growth Trend - The change in the growth score over the given time period
Heat Score - The measure of the market interest, media activity, and Crunchbase profile activity
Heat Trend - The change in the heat score over the given time period
Learn More >
Recent Milestones
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
See more interactive data and historical milestones on desktop for the best experience

About VIVUS

CB Rank
110197
VIVUS is a drug-development company dedicated to the development and commercialization of next-generation therapeutic products
Founded
obfuscation
PublicPost-IPO Equity Mountain View, California, United States51-100 www.vivus.com
Biopharma
Biotechnology
Health Care

Funding Rounds

Post-IPO Equity
OBF
in
obfuscation
Post-IPO Debt
OBF
in
obfuscation
Post-IPO Equity
OBF
in
obfuscation

Key People

Details

Legal Name VIVUS LLC
Operating Status Active
Stock Symbol  NASDAQ:VVUS
Company Type For Profit
About the Company
VIVUS, Inc. is a drug-development company dedicated to the development and commercialization of next-generation therapeutic products addressing obesity, diabetes, sleep apnea and sexual health.
Phone Number +1 6509345389
Contact Email sunshineact@vivus.com
Predictions & Insights

Growth Insight

See this Growth Insight
VIVUS is
Lorem
 to be growing
Top Contributing Factors
Market Share Expansion

Products & Services

PANCREAZE
A pancreatic enzyme replacement therapy used to manage exocrine pancreatic insufficiency (EPI).
QSYMIA
A prescription medication for weight management, available through pharmacies including Costco.

Unlock More with Crunchbase Pro
  • Full access to financial & funding data on unlimited profiles
  • Export up to 2k results/month for analysis
  • Track market signals on competitors, products, and R&D
  • Preview private company insights and predictions
Financials

Company Funding

Total Funding Amount 
obfuscation
Number of Funding Rounds 5
Unlock company funding data, including rounds, dates, amounts, and investors.
Announced Date  
Transaction Name  
Number of Investors  
Money Raised  
Lead Investors  
Funding Type  
obfuscation
Post-IPO Equity - VIVUS Logo
Post-IPO Equity - VIVUS
5
obfuscation
Caxton Advantage Life Sciences FundPost-IPO Equity
obfuscation
Post-IPO Equity - VIVUS Logo
Post-IPO Equity - VIVUS
5
obfuscation
Caxton Advantage Life Sciences FundPost-IPO Equity
obfuscation
Post-IPO Equity - VIVUS Logo
Post-IPO Equity - VIVUS
5
obfuscation
Caxton Advantage Life Sciences FundPost-IPO Equity
obfuscation
Post-IPO Equity - VIVUS Logo
Post-IPO Equity - VIVUS
5
obfuscation
Caxton Advantage Life Sciences FundPost-IPO Equity
obfuscation
Post-IPO Equity - VIVUS Logo
Post-IPO Equity - VIVUS
5
obfuscation
Caxton Advantage Life Sciences FundPost-IPO Equity

Funding Rounds

Total Funding Amount 
obfuscation
Number of Funding Rounds 5
Unlock company funding data, including rounds, dates, amounts, and investors.
Announced Date  
Transaction Name  
Number of Investors  
Money Raised  
Lead Investors  
Funding Type  
obfuscation
Post-IPO Equity - VIVUS Logo
Post-IPO Equity - VIVUS
5
obfuscation
Caxton Advantage Life Sciences FundPost-IPO Equity
obfuscation
Post-IPO Equity - VIVUS Logo
Post-IPO Equity - VIVUS
5
obfuscation
Caxton Advantage Life Sciences FundPost-IPO Equity
obfuscation
Post-IPO Equity - VIVUS Logo
Post-IPO Equity - VIVUS
5
obfuscation
Caxton Advantage Life Sciences FundPost-IPO Equity
obfuscation
Post-IPO Equity - VIVUS Logo
Post-IPO Equity - VIVUS
5
obfuscation
Caxton Advantage Life Sciences FundPost-IPO Equity
obfuscation
Post-IPO Equity - VIVUS Logo
Post-IPO Equity - VIVUS
5
obfuscation
Caxton Advantage Life Sciences FundPost-IPO Equity

Investors

Unlock company funding data, including rounds, dates, amounts, and investors.
Investor Name  
Lead Investor  
Funding Round  
Partners  
Franklin Templeton Logo
Franklin Templeton
—
Post-IPO Equity - VIVUS Logo
Post-IPO Equity - VIVUS
—
Franklin Templeton Logo
Franklin Templeton
—
Post-IPO Equity - VIVUS Logo
Post-IPO Equity - VIVUS
—
Franklin Templeton Logo
Franklin Templeton
—
Post-IPO Equity - VIVUS Logo
Post-IPO Equity - VIVUS
—
Franklin Templeton Logo
Franklin Templeton
—
Post-IPO Equity - VIVUS Logo
Post-IPO Equity - VIVUS
—
Franklin Templeton Logo
Franklin Templeton
—
Post-IPO Equity - VIVUS Logo
Post-IPO Equity - VIVUS
—
Market Intelligence
People
View Profiles & Contacts
Headcount 51-100 Employee Profiles 3 Contacts 55

Employee Profiles

News

News and Press

News•Apr 30, 2026
obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated
News•Mar 25, 2026
obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated
News•Mar 25, 2026
obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated
News•Mar 10, 2026
obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated
Access a complete feed of recent news and press, from product launches to leadership changes.
Technology
View Tech Report

Monthly Web Visits

5,310
132.39%
 in past month

IT Spend

$1.1MThis year, VIVUS is projected to spend $1.1M on IT, according to Aberdeen.

Interest Signals

TopicSurge Score
Quest Logo
Quest
100
JFrog Logo
JFrog
98
Livingetc Logo
Livingetc
95

Actively Used Products

18VIVUS uses 18 technology products and services including HTML5, Google Analytics, and  Symantec Email Security.Cloud, according to G2 Stack.

Active Website Tech Count

19VIVUS is actively using 19 technologies for its website, according to BuiltWith. These include HSTS, DNSSEC, and  Google Maps.

Total IP

19The intellectual property of VIVUS includes 19 registered patents primarily in the 'Medical Or Veterinary Science; Hygiene' category, according to IPqwery.
Sub-Organizations
Frequently Asked Questions

Where is VIVUS's headquarters? VIVUS is located in Mountain View, California, United States.Who invested in VIVUS? VIVUS has 9 investors including Franklin Templeton and  EuclidSR Partners.When was the last funding round for VIVUS? VIVUS closed its last funding round on
obfuscation
from a Post-IPO Equity round.Who are VIVUS's competitors? Alternatives and possible competitors to VIVUS may include Sucraid, Invictus, and  Loomis Enzymes.How much funding has VIVUS raised to date? VIVUS has raised
obfuscation
.
Who We Are
What We Do
Helpful Links
AI Content may contain mistakes and is not legal, financial or investment advice. Learn more.
Terms of Service | Privacy Policy | Sitemap | © 2026 Crunchbase Inc. All Rights Reserved.
(9fd75b2 1)
|